Skip to content

Functional Chewing Gum in Reduction of Gingival Inflammation

Use of a Functional Chewing Gum in Reduction of Gingival Inflammation

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03237624
Enrollment
34
Registered
2017-08-02
Start date
2018-01-31
Completion date
2020-01-31
Last updated
2024-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingivitis

Keywords

gingivitis

Brief summary

The aim of this prospective randomized 3-month double-blinded single center study is to determine whether a chewing gum device with food additive chitosan, will aid in reducing gingival inflammation by supplementing traditional tooth brushing and flossing measures. Patients with mild to moderate gingivitis will be identified and enrolled in this investigation. All enrolled subjects will receive baseline oral hygiene brushing instructions and a baseline clinical examination of the gingiva. The test group will utilize the test chewing gum three times a day for a minimum 20-30 minutes duration; the control group will receive a placebo gum and use it in a similar manner. We will examine whether daily use of a functional chewing gum enhances improvements to brushing and flossing.

Detailed description

Periodontal disease remains a prevalent and preventable disease in man. Plaque bacterial biofilm remains the primary etiologic agent of disease; colonization of non-shedding tooth surfaces greatly contributes to initiation and progression of gingivitis, for example. Although there are currently available chemotherapeutic agents to supplement daily oral hygiene measures, one continuous issue is patient compliance. Chewing gum represents a unique delivery device for not only drugs and other agents, but food additives that might aid in reducing bacteria plaque colonization on tooth surfaces. For example, chitosan and chitosan-related food additive preparations have been shown to have some antimicrobial-like properties, possibly in the disruption of bacterial colonization (not -cidal). NOTE: ALL INGREDIENTS of the test chewing gum, and the placebo chewing gum, are generally regarded as safe (GRAS label by the Food and Drug Administration), as they are common food components. For example, chitosan is listed in the GRAS database (https://www.accessdata.fda.gov/scripts/fdcc/?set=SCOGS). See item GRN No. 397. This study aims to determine whether adjunctive use of functional chewing gum will improve gingival inflammation status-retaining clinical gains initiated by professional tooth cleaning and at home brushing over a 12 week period in gingivitis patients. Eligibility criteria and outcome measures are described in the next section.

Interventions

DEVICEFunctional Chitosan Chewing Gum

Chitosan and chitosan-related preparations have been shown to have some antimicrobial properties, possibly in the disruption of bacterial colonization. It is thought that as a component of a functional chewing gum this will supplement in the removal of daily build up of dental plaque on tooth surfaces.

DEVICEControl Chewing Gum

Control chewing gum device does not have food additive chitosan in its composition.

BEHAVIORALOral hygiene measures

Patients will be given instructions on how to brush and floss routinely (twice per day)

Sponsors

University of Maryland, Baltimore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Mild-moderate gingivitis * Minimum of 20 natural teeth

Exclusion criteria

* Significant alveolar bone loss as evidenced by Bite-wings (\>3.0 mm cementoenamel junction to bone) * Requirement for antibiotic pre-medication prior to dental procedures * Systemic antibiotic use in past 14 days to current. * Use of oral contraceptives * Use of anti-inflammatory (NSAIDs) or in past 14 days. * Use of anticoagulant therapy or in past 14 days. * Poorly controlled diabetes (HbA1c \> 7.9%)\* * Smoking * Pregnancy * Use of any oral rinses such as, but not limited to chlorhexidine, essential oils, cetylpyridinium chloride during the study.

Design outcomes

Primary

MeasureTime frameDescription
Gum inflammation changeChange in color of gingiva from baseline to 12 weeksMeasure the color of gingiva - use Gingiva Index

Secondary

MeasureTime frameDescription
Plaque levels (on teeth) changeChange in plaque level from baseline to 12 weeksMeasure plaque using Plaque Index

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026